Abstract
A multi-center comparative study of Atezolizumab plus Bevacivumab and Lenvatinib as primary systemic therapy for unresectable hepatocellular carcinoma (HCC): focus on thrombotic and hemorrhagic adverse events
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have